Moderate Asthma
Conditions
Keywords
Asthma
Brief summary
The goal of this interventional study is to compare at-home mobile spirometry to in-clinic spirometry in participants with moderate asthma while taking a long-acting beta agonist (LABA). The main questions it aims to answer are: * Do at-home mobile spirometry and in-clinic spirometry assessments show a similar treatment effect (measured changes in FEV1) with the addition of LABA? * Is at-home mobile spirometry as accurate as in-clinic spirometry in showing treatment effects (changes in FEV1)? Participants will be asked to: * Take standard of care LABA treatment once or twice a day * Complete at-home mobile spirometry testing twice a day * Complete asthma questionnaires twice a day * Complete device use questionnaires * Wear a wrist device (like a watch) to track physical activity and vital signs * Visit the clinic for in-clinic spirometry testing once a week for 8 weeks
Detailed description
The study will recruit up to 60 participants with moderate uncontrolled asthma who are taking inhaled corticosteroids (ICS) at the time of study enrollment but will require LABA treatment as judged by their treating physician. The study will assess the LABA treatment effect in clinic and mobile spirometry, assess the relationship between different readouts of mobile spirometry in addition to assessing asthma control as measured by ACQ-6, patient reported outcome questionnaire. Additional objectives include an evaluation of patient and site-specific satisfaction with mobile spirometry technology. The study consists of a one-week screening period, one-week baseline period, and up to 6-week interventional assessment period consisting of addition of LABA, for an estimated participant duration of 8 weeks.
Interventions
DRUGLong-Acting Beta Agonist
The Investigator will prescribe standard of care LABA to eligible study participants. Participants will self-administer LABA once or twice daily at the maximum feasible standard of care dosage, per the time points specified in the study Schedule of Assessments. LABA should be taken within 1 to 3 hours prior to morning and evening at-home mobile Spirometry testing.
Sponsors
Koneksa Health
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Intervention model description
Long-Acting Beta Agonist
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Individuals 18 years or older 2. Body mass index (BMI) 18 - 40 mg/m2 inclusive 3. Participant with a diagnosis of moderate uncontrolled asthma 4. Participant must be using a medium to high daily dose of inhaled corticosteroids (ICS) for a minimum of 6 weeks prior to screening 5. Asthma that is not currently using long-acting beta-agonists (LABA) or log-acting muscarinic antagonist (LAMA) (ACQ score of 0.75 or higher) Note: A 2-week LABA/LAMA washout period is allowed prior to screening 6. Pre-bronchodilator FEV1 ≥ 60% and ≤100% of the predicted normal values at screening 7. A documented positive response to the reversibility test at screening, defined as improvement in FEV1 ≥ 12% and ≥ 200 mL over baseline after a Short Acting Beta Agonist (SABA) standard of care dose. Documented historical reversibility of up to 6 weeks is allowed. 8. Participant is judged to be in good health based on medical history, physical examination, and vital sign measurements 9. Non-smokers or ex-smokers (including vape or inhaled cannabis) who have stopped smoking more than 1 year ago 10. Women of childbearing potential must have a negative urine pregnancy test before enrolling at Baseline Day 1 11. Participant demonstrated ability to perform satisfactory in-clinic and at-home Spirometry according to ATS/ERS standards, as well as the mobile application to synchronize Spirometry data collection and respond to questionnaires during the Screening coaching/training period
Exclusion criteria
1. History of life-threatening asthma, defined as an asthma episode that required intubation and/or was associated with hypercapnia, respiratory arrest and/or hypoxic seizures or hospitalization (including ER visits) for the treatment of asthma within 3 months prior to screening, or have been hospitalized or have attended the ER for asthma more than twice in prior 6 months 2. Occurrence of asthma exacerbations or respiratory tract infections within 4 weeks prior to Screening 3. History of substance abuse in the last 6 months, excluding medical or recreational non- inhaled marijuana 4. Currently taking other biologics to control asthma symptoms (allergy shots are acceptable) 5. Diagnosis of any other airway/pulmonary disease such as Chronic Obstructive Pulmonary Disease (COPD) as defined by the current Global Initiative for Chronic Obstructive Lung Disease (GOLD) guidelines; or other lung diseases (e.g., emphysema, idiopathic pulmonary fibrosis, Churg-Strauss syndrome, allergic bronchopulmonary aspergillosis cystic fibrosis, bronchiectasis or alpha-1 antitrypsin deficiency or restrictive lung disease) 6. Clinically unstable participants or history of non-compliance as assessed by the PI 7. Chronic or acute infection requiring treatment with systemic antibiotics, antivirals, or antifungals within 1 month prior to screening 8. Participant has a history of neoplastic disease. Exceptions: Participants with (1) an adequately treated basal or squamous cell carcinoma or carcinoma in situ of the cervix; (2) localized or regional prostate cancer; other malignancies which have been successfully treated \> 5 years prior to screening without evidence of recurrence may participate 9. Participants treated with oral or parenteral corticosteroids in the previous 4 weeks prior to screening 10. You may not be able to participate in this study if you have been in another investigational drug study for 30 days prior to this study unless approval is given from the Sponsor. Additionally, you cannot be involved in another investigational drug study during your participation in this study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Measured FEV1 Change to Treatment Effect | Baseline Day 1 through Day 43 End of Study | Detection of treatment effect as measured by change from baseline in morning FEV1 measured in change over time for at-home mobile and in-clinic Spirometry |
| Measured FEV1 Change and Comparison of Variability | Baseline Day 1 through Day 43 End of Study | Change from baseline and comparison of variability (measured via confidence interval) in morning FEV1 for at-home morning mSpirometry compared to morning in-clinic Spirometry |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Diurnal Differences in Mobile Spirometry | Baseline Day 1 through Day 43 End of Study | Diurnal differences in morning versus evening for at-home mSpirometry parameters, e.g., FEV1 |
| Time to Treatment Effect | Baseline Day 1 through Day 43 End of Study | Time to treatment effect detection using at-home mSpirometry via change in FEV1 |
| Mobile Spirometry Compliance | Baseline Day 1 through Day 43 End of Study | Percentage of compliance for once and twice daily at-home mSpirometry |
| Mobile Spirometry Changes | Baseline Day 1 through Day 43 End of Study | Relationship between at-home mSpirometry changes and changes in ACQ-6 |
| Device Use Surveys | Baseline Day 1 through Day 43 End of Study | 1. Site clinical care team likelihood to recommend at-home mSpirometry 2. Site clinical care team ease-of-use of at-home mSpirometry 3. Site clinical care team device satisfaction 4. Participant likelihood to recommend at-home mSpirometry 5. Participant ease-of-use of at-home mSpirometry 6. Participant device satisfaction |
| Treatment Effect | Baseline Day 1 through Day 43 End of Study | Treatment effect as measured by change from baseline in ACQ-6 |
| Relationship Between In-clinic and Mobile Spirometry Parameters | Baseline Day 1 through Day 43 End of Study | 1. Evaluate the relationship between in-clinic and mSpirometry FEV1 and other Spirometry parameters (e.g., FVC) 2. Relationship between other Spirometry measurements (e.g., FVC) |
Countries
United States
Outcome results
None listed